Dr. Ruan on Classifying T-cell Lymphomas

Video

Jia Ruan, MD, PhD, associate professor of Clinical Medicine, Division of Hematology and Medical Oncology at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the classification of T-cell lymphomas.

Jia Ruan, MD, PhD, associate professor of Clinical Medicine, Division of Hematology and Medical Oncology at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the classification of T-cell lymphomas.

T-cell lymphoma is a very rare subtype; approximately 5% to 10% of patients with non-Hodgkin lymphoma have this disease, Ruan explains. It is also very heterogenous and difficult to treat. The long-term outcomes for patients with T-cell lymphoma remain to be suboptimal. Studies show that there is a 20% to 30% 5-year overall survival rate, so there is room for improvement, she adds.

Ongoing clinical trials in this area are focused on intensifying chemotherapy regimens or incorporating novel agents to improve effectiveness and induce complete remissions.

Related Videos
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Eric S. Christenson, MD
Samer A. Srour, MB ChB, MS
Rebecca L. Porter, MD, PhD
Deborah J. Wong, MD, PhD
Michael R. Migden, MD
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO